• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Statistical analysis plan for evaluating low‐ vs. standard‐dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED)
ConclusionsWe have developed a predetermined statistical analysis plan for the ENhanced Control of Hypertension And Thrombolysis strokE stuDy alteplase dose arm which is to be followed to avoid analysis bias arising from prior knowledge of the study findings.
Source: International Journal of Stroke - August 18, 2015 Category: Neurology Authors: Craig S. Anderson, Mark Woodward, Hisatomi Arima, Xiaoying Chen, Richard I. Lindley, Xia Wang, John Chalmers, Tags: Protocol Source Type: research

Statistical analysis plan for evaluating low ‐ vs. standard‐dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED)
International Journal of Stroke,Volume 10, Issue 8, Page 1313-1315, December 2015.
Source: International Journal of Stroke - August 18, 2015 Category: Neurology Source Type: research

Burden of stroke in Italy: An economic model highlights savings arising from reduced disability following thrombolysis
ConclusionOur study reveals that performing thrombolytic therapy in eligible patients improves economic outcomes compared with patients receiving standard care. This model is useful for decision makers, both within and outside of the Italian national context, as a tool to assess the cost‐effectiveness of thrombolysis in both short‐ and long‐term period.
Source: International Journal of Stroke - April 8, 2015 Category: Neurology Authors: M. Chiumente, M. M. Gianino, D. Minniti, T. J. Mattei, B. Spass, K. M. Kamal, D. E. Zimmerman, A. Muca, E. Luda Tags: Research Source Type: research

THrombolysis for Acute Wake‐up and unclear‐onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial
DiscussionThis trial may help determine if low‐dose alteplase at 0·6 mg/kg should be recommended as a routine clinical strategy for ischemic stroke patients with unclear‐onset time.
Source: International Journal of Stroke - August 4, 2014 Category: Neurology Authors: Masatoshi Koga, Kazunori Toyoda, Kazumi Kimura, Haruko Yamamoto, Makoto Sasaki, Toshimitsu Hamasaki, Takanari Kitazono, Junya Aoki, Kenta Seki, Kazunari Homma, Shoichiro Sato, Kazuo Minematsu, Tags: Protocols Source Type: research

Doubling in use of alteplase in Australia between 2003 and 2009
Source: International Journal of Stroke - July 17, 2014 Category: Neurology Authors: Janet K. Sluggett, Gillian E. Caughey, Michael B. Ward, Andrew L. Gilbert Tags: Letter to the editor Source Type: research

The effect of time to treatment on outcome in very elderly thrombolysed stroke patients
ConclusionsIn this nonrandomized comparison, the relationship of benefit and safety with thrombolysis across onset time to treatment in very elderly stroke patients was comparable with that in their younger counterparts. Across the investigated time span of 3·5 h, we can safely treat with the same time window as we use for younger patients.
Source: International Journal of Stroke - March 3, 2014 Category: Neurology Authors: Benedikt Frank, Rachael L. Fulton, Kennedy R. Lees, Tags: Research Source Type: research

REVASCAT: a randomized trial of revascularization with SOLITAIRE FR® device vs. best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight‐hours of symptom onset
REVASCAT is a prospective, multicenter, randomized trial seeking to establish whether subjects meeting following main inclusion criteria: age 18‐80, baseline National Institutes of Health Stroke Scale ≥6, evidence of intracranial internal carotid artery or proximal (M1 segment) middle cerebral artery occlusion, Alberta Stroke Program Early Computed Tomography score of >7 on non‐contrast CT or >6 on diffusion‐weighted magnetic resonance imaging , ineligible for or with persistent occlusion after intravenous alteplase and procedure start within 8 hours from symptom onset, have higher rates of favorable outcome ...
Source: International Journal of Stroke - November 10, 2013 Category: Neurology Authors: Carlos A. Molina, Angel Chamorro, Àlex Rovira, Angeles Miquel, Joaquin Serena, Luis San Roman, Tudor G. Jovin, Antoni Davalos, Erik Cobo Tags: Protocols Source Type: research

Details of a prospective protocol for a collaborative meta‐analysis of individual participant data from all randomized trials of intravenous rt‐PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists’ Collaborative meta‐analysis
We describe the protocol for an updated individual patient data meta‐analysis of trials of intravenous alteplase, including results from the recently reported third International Stroke Trial, in which a wide range of patients enrolled up to six‐hours after stroke onset were randomized to alteplase vs. control. Study OutcomesThis protocol will specify the primary outcome for efficacy, specified prior to knowledge of the results from the third International Stroke Trial, as the proportion of patients having a ‘favorable’ stroke outcome, defined by modified Rankin Score 0–1 at final follow‐up at three‐ to six�...
Source: International Journal of Stroke - April 1, 2013 Category: Neurology Tags: Protocol Source Type: research

Protocol for the perfusion and angiography imaging sub‐study of the Third International Stroke Trial (IST‐3) of alteplase treatment within six‐hours of acute ischemic stroke
RationaleIntravenous thrombolysis with recombinant tissue Plasminogen Activator improves outcomes in patients treated early after stroke but at the risk of causing intracranial hemorrhage. Restricting recombinant tissue Plasminogen Activator use to patients with evidence of still salvageable tissue, or with definite arterial occlusion, might help reduce risk, increase benefit and identify patients for treatment at late time windows. AimsTo determine if perfusion or angiographic imaging with computed tomography or magnetic resonance help identify patients who are more likely to benefit from recombinant tissue Plasminogen Ac...
Source: International Journal of Stroke - January 22, 2013 Category: Neurology Authors: Joanna M. Wardlaw, Rudiger Kummer, Trevor Carpenter, Mark Parsons, Richard I. Lindley, Geoff Cohen, Veronica Murray, Adam Kobayashi, Andre Peeters, Francesca Chappell, Peter A. G. Sandercock Tags: Protocols Source Type: research

Selection for delayed intravenous alteplase treatment based on a prognostic score
ConclusionSelection of patients between 4·5 and 6 h based on simple clinical measures failed to deliver a population in whom the alteplase effect would be safe and effective.
Source: International Journal of Stroke - January 7, 2013 Category: Neurology Authors: Rachael L Fulton, Kennedy R Lees, Erich Bluhmki, Gabriele Biegert, Gregory W Albers, Stephen M Davis, Geoffrey A Donnan, James C Grotta, Werner Hacke, Markku Kaste, Rüdiger von Kummer, Ashfaq Shuaib, Danilo Toni, , A. Alexandrov, P.W. Bath, L. Claesson, Tags: Research Source Type: research